(Nasdaq:GNMX) Aevi Genomic Medicine Inc Lowers The 52 Week Low

Aevi Genomic Medicine Inc (Nasdaq:GNMX)

July 13th, 2018

With markets going up Aevi Genomic Medicine Inc fell $0.04 Friday, a 3.99% drop, closing at $0.96. As well as the drop in value, Aevi Genomic Medicine Inc hit a new 52 week low of $0.95, breaking the previous low of $0.98 from earlier this month. In addition to the stock finishing lower, the trading volumes were only 33% of normal which could be an indication of investor uncertainty.

GNMX was outperformed by the rest of the Healthcare sector which went up 0.23%.

Aevi Genomic Medicine Inc Info

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company’s lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn’s disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

All amounts in USD unless otherwise indicated

GNMX daily update
GNMX daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.